Literature DB >> 12127667

Quality of life and cost of multiple sclerosis.

Carolin Miltenburger1, Gisela Kobelt.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12127667     DOI： 10.1016/s0303-8467(02)00051-3

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN： 0303-8467            Impact factor:   1.876


× No keyword cloud information.
  14 in total

1.  Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors:  Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

2.  An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis.

Authors:  Francesco Lolli; Barbara Mulinacci; Alfonso Carotenuto; Bruno Bonetti; Giuseppina Sabatino; Benedetta Mazzanti; Anna Maria D'Ursi; Ettore Novellino; Marta Pazzagli; Laura Lovato; Maria C Alcaro; Elisa Peroni; Maria C Pozo-Carrero; Francesca Nuti; Luca Battistini; Giovanna Borsellino; Mario Chelli; Paolo Rovero; Anna Maria Papini
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-12       Impact factor: 11.205

Review 3.  Economic burden of multiple sclerosis: a systematic review of the literature.

Authors:  Huseyin Naci; Rachael Fleurence; Julie Birt; Amy Duhig
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 4.  Early intervention in multiple sclerosis : better outcomes for patients and society?

Authors:  Peter Flachenecker; Peter Rieckmann
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.

Authors:  Ceri J Phillips
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  Paul L McCormack; Lesley J Scott
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.

Authors:  Stephanie C Steinberg; Richard J Faris; Cyril F Chang; Andrew Chan; Mark A Tankersley
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

8.  [Health care costs of multiple sclerosis in Austria. Cross-sectional study including consideration of quality of life].

Authors:  U Ganzinger; C Badelt; K Vass; S Strasser-Fuchs; F Fazekas; T Berger; F Dahlke
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

9.  Pain due to multiple sclerosis: analysis of the prevalence and economic burden in Canada.

Authors:  Charles Piwko; Olivier B Desjardins; Basil G Bereza; Marcio Machado; Barbara Jaszewski; Mark S Freedman; Thomas R Einarson; Michael Iskedjian
Journal:  Pain Res Manag       Date:  2007       Impact factor: 3.037

10.  Assessing cost-effectiveness in the management of multiple sclerosis.

Authors:  Ceri J Phillips; Ioan Humphreys
Journal:  Clinicoecon Outcomes Res       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.